Results 81 to 90 of about 410,880 (314)

High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer [PDF]

, 2005
Background: Docetaxel is one of the most effective antitumor agents currently available for the treatment of metastatic breast cancer (MBC). This phase II multicenter study prospectively analyzed the efficacy and toxicity of docetaxel given on a weekly ...
Abenhardt, Wolfgang, Leinung, S., V. Heinemann, Stemmler, J., W. Mair, Jackisch, C., O. Brudler, G. Deutsch, Stamp, J., Dorn, B., J. Stemmler, Brudler, O., Stauch, M., M. Malekmohammadi, Papke, J., M. Stauch, Deutsch, G., Vehling-Kaiser, U., S. Leinung, B. Dorn, Heinemann, Volker, C. Jackisch, U. Vehling-Kaiser, Mair, W., Kentenich, C., J. Papke, C. Kentenich, Malekmohammadi, M., W. Abenhardt, J. Stamp   +29 more
core   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

Options for early breast cancer follow-up in primary and secondary care : a systematic review [PDF]

, 2012
Background Both incidence of breast cancer and survival have increased in recent years and there is a need to review follow up strategies. This study aims to assess the evidence for benefits of follow-up in different settings for women who have had ...
Peter Donnelly, Dunn, Janet A., Dunn Janet, Donnelly Peter, Frances Taggart, Taggart Frances, Taggart, Frances M., Donnelly, Peter K., Janet Dunn   +8 more
core   +1 more source

Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2− advanced breast cancer in five European countries

BMC Cancer, 2020
Background Endocrine therapy (ET)-based regimens are the mainstay of treatment for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer.
Alison Davie, Gebra Cuyun Carter, Alex Rider, James Pike, Katie Lewis, Abigail Bailey, Gregory L. Price, Francois Ringeisen, Xavier Pivot   +8 more
doaj   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

An integrated model of the transcriptome of HER2-positive breast cancer [PDF]

, 2013
Our goal in these analyses was to use genomic features from a test set of primary breast tumors to build an integrated transcriptome landscape model that makes relevant hypothetical predictions about the biological and/or clinical behavior of HER2 ...
Melissa Lau, High-seng Chai, David Rossell, Brian M. Necela (224867), Jeanette E. Eckel-Passow (228909), S. Keith Anderson (271824), Tang, Xiaojia, Rossell, David, Kevin J. Thompson (479037), E. Aubrey Thompson (224877), Sarah A McLaughlin, Baker, Tiffany R., Kalari, Krishna R., Necela, Brian M., Xiaojia Tang, Melissa Lau (479038), David Rossell (479046), Lau, Melissa, Derek C Radisky, Krishna R. Kalari (228899), Richard W. Joseph (479042), Sarah A. McLaughlin (479043), Camille, Stephan, Thompson, E. Aubrey, McLaughlin, Sarah A., S Keith Anderson, Saurabh Baheti, Tiffany R Baker, Jennifer M Kachergus, Jennifer M Carr, Joseph, Richard W., Asmann, Yan W., Kachergus, Jennifer M., Yan W. Asmann (210163), Zhifu Sun (60356), Derek C. Radisky (119628), Carr, Jennifer M., Richard W Joseph, Krishna R Kalari, Jennifer M. Carr (224872), Thompson, Kevin J., High-seng Chai (479044), Stephan Camille (479045), Kevin J Thompson, Poulami Barman (479041), Poulami Barman, Edith A Perez, Xiaojia Tang (53518), Saurabh Baheti (479040), Anderson, S. Keith, Barman, Poulami, Brian M Necela, Stephan Camille, Radisky, Derek C., Jennifer M. Kachergus (479039), Eckel-Passow, Jeanette E., Chai, High-seng, Perez, Edith A., Sun, Zhifu, E Aubrey Thompson, Yan W Asmann, Tiffany R. Baker (228915), Zhifu Sun, Baheti, Saurabh, Edith A. Perez (228921), Jeanette E Eckel-Passow   +65 more
core   +1 more source

Adjuvant chemotherapy of megestrol acetate in advanced breast cancer: A meta-analysis

Bangladesh Journal of Pharmacology, 2015
To evaluate the effectiveness and safety of adjuvant chemotherapy of megestrol acetate (MA) in advanced breast cancer, we searched CBM, CNKI, VIP, Wangfang Data and PubMed, and collected randomized controlled trials (RCT) of adjuvant chemotherapy of MA ...
Yanping Shui, Youmei Tang, Xuefeng Zhang, Jun Ge, Zhichen Pu   +4 more
doaj  

Prognostic Impact of Stimulator of Interferon Genes Expression in Triple Negative Breast Cancer

Cancer Medicine
Background Patients with triple negative breast cancer (TNBC) who have a poor response to neoadjuvant chemotherapy (NAC) have worse survival and new treatment strategies need to be developed.
Tetsuyo Maeda, Makiko Ono, Tomo Osako, Tomohiro Chiba, Satoko Baba, Asumi Iesato, Yukinori Ozaki, Yuka Inoue, Natsue Uehiro, Yoko Takahashi, Takayuki Kobayashi, Takahiro Kogawa, Tomohiko Ohta, Shigehisa Kitano, Takayuki Ueno, Shinji Ohno   +15 more
doaj   +1 more source

“My experience has been a terrible one, something I could not run away from”: Zambian women’s experiences of advanced breast cancer

International Journal of Africa Nursing Sciences, 2015
Breast cancer is the most common cancer in women worldwide and the second most common cancer in women treated at the Cancer Diseases Hospital in Zambia. Unfortunately most women present with advanced disease, too late to be cured.
Johanna E. Maree, J. Mulonda
doaj   +1 more source

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source